ArticleInternational journal of hematology2026
Post-hoc analysis of induction failure in pediatric LCH: the JLSG-02 and LCH-12 clinical trials.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Treatment options for refractory multisystem Langerhans cell histiocytosis (LCH) were not well established prior to the era of targeted therapy. We evaluated the efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like salvage regimen (Induction B) in patients with induction failure in a post-hoc analysis of the JLSG-02 (N = 147) and JPLSG LCH-12 (N = 107) studies of pediatric LCH. Of 254 patients, 41 were refractory (no response or progressive disease) following initial Induction A therapy (prednisolone, vincristine, and cytarabine). Among them, 35 patients who received Induction B therapy were analyzed. The overall response rate to Induction B was 66% (23/35). Sixteen patients (46%) achieved no active disease after Induction B followed by maintenance therapy; among them, six patients with risk organ involvement (RO+) relapsed. The 5-year overall survival was 100% in the RO- group and 84.6% (95% CI, 64.0-93.9%) in the RO+ group. Grade 3/4 hematological toxicities were frequent; however, no fatal adverse events were observed. Induction B demonstrated efficacy and an acceptable safety profile in pediatric refractory multisystem LCH. This therapy could be a salvage treatment option for patients with refractory disease when targeted therapy is not available.
Indexed as
Identifiers
42832019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.